Retatrutide vs Tirzepatide: Dosage, Efficacy & Mechanism
A side-by-side, peer-reviewed comparison of Retatrutide and Tirzepatide — mechanism, typical research dose and titration, clinical-trial efficacy, administration, and reconstitution. For research and educational purposes only.
| Attribute | Retatrutide | Tirzepatide |
|---|---|---|
| Drug class | Weight Loss | Weight Loss |
| Mechanism of action | Retatrutide is a 39-amino-acid synthetic peptide with C20 fatty-acid acylation that drives albumin binding and yields a terminal half-life of approximately six days, enabling weekly subcutaneous administration . Unlike single-incretin agents, it engages… | Tirzepatide is engineered around a modified GIP backbone with C20 fatty-diacid acylation that binds albumin to produce a terminal half-life of roughly 5 days, allowing fixed-dose weekly subcutaneous injection . The molecule is a balanced agonist at the GIP… |
| Typical research dose | 2–8 mg once weekly (gradual escalation over 8–12 weeks). | 2.5–15 mg once weekly (gradual 4‑week titration steps). |
| Headline trial efficacy | An exploratory analysis showed dose-dependent reductions in waist circumference of up to 17.8 cm at 48 weeks on 12 mg, paralleling the substantial visceral-fat loss seen on imaging . | SUMMIT (Packer et al., NEJM 2024) showed tirzepatide reduced the composite of cardiovascular death and worsening heart failure by 38% in patients with obesity-related HFpEF, suggesting cardiovascular benefit beyond glycemia and weight. |
| Administration | Refer to guidelines | Refer to guidelines |
| Vial sizes | 5 mg, 10 mg, 20 mg, 30 mg | 5 mg, 10 mg, 15 mg, 30 mg |
| Storage | Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F) for up to 4 weeks[16]. | Lyophilized frozen; reconstituted refrigerated for up to 28 days. |
Frequently Asked Questions
What is the difference between Retatrutide and Tirzepatide?expand_more
Retatrutide (weight loss) and Tirzepatide (weight loss) differ in receptor target and mechanism. Retatrutide is a 39-amino-acid synthetic peptide with C20 fatty-acid acylation that drives albumin binding and yields a terminal half-life of approximately six days, enabling weekly subcutaneous administration . Unlike single-incretin agents, it engages… By contrast, tirzepatide: Tirzepatide is engineered around a modified GIP backbone with C20 fatty-diacid acylation that binds albumin to produce a terminal half-life of roughly 5 days, allowing fixed-dose weekly subcutaneous injection . The molecule is a balanced agonist at the GIP…
How do the typical research doses of Retatrutide and Tirzepatide compare?expand_more
Retatrutide is typically dosed at 2–8 mg once weekly (gradual escalation over 8–12 weeks)., while Tirzepatide is typically dosed at 2.5–15 mg once weekly (gradual 4‑week titration steps).. See each protocol for the full titration schedule.